Centiva Capital’s Serina Therapeutics SER Stock Holding History

Centiva Capital’s Portfolio SER Stock Details SER Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-788	Closed	-$26K	–	906
2020 Q2	$26K	Buy	+788	New	+$23.2K	﹤0.01%	626

Other funds holding SER

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

SWIG

Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Centiva Capital's SER Position: Q3 2020 in Review

Centiva Capital sold out of Serina Therapeutics (SER) in Q3 2020, closing a stake of 788 shares — an estimated $26K sold.

Centiva Capital first reported a position in SER in Q2 2020 and held it in 1 quarter. The position peaked at $26K in Q2 2020. 36 funds tracked by Wall St. Rank hold SER as of Q3 2020.

Centiva Capital reported no remaining Serina Therapeutics position as of Q3 2020 after selling out during the quarter.
Centiva Capital sold 788 Serina Therapeutics shares in Q3 2020, an estimated $26K.
Centiva Capital first reported a position in Serina Therapeutics in Q2 2020 and held it in 1 quarter.
Centiva Capital's Serina Therapeutics position peaked at $26K in Q2 2020.
36 funds tracked by Wall St. Rank held Serina Therapeutics as of Q3 2020.

Based on Centiva Capital's 13F filing for Q3 2020, filed 16 Nov 2020.